A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY).
S. A. Limentani
Research Funding - Lilly
H. Burris
Research Funding - Lilly
A. P. Anderson
Research Funding - Lilly
L. H. Brail
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
D. Satonin
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
I. Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
S. Jones
No relevant relationships to disclose
J. R. Infante
No relevant relationships to disclose
J. C. Bendell
No relevant relationships to disclose